Investigational drug · Phase 2
GenSci120
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.
Phase 2Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GenSci120"
First trial start
2026
Apr 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GenSci120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "GenSci120" as an intervention, largest first.
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARDPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07423533 · 450 participants (planned) · Start Apr 30, 2026 · Primary completion Sep 2027
Drug: GenSci120 150 mg; GenSci120 600 mg and 3 more · For: Rheumatoid Arthritis
Sites: Beijing, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06827457 · 58 participants · Start Feb 20, 2025 · Primary completion Nov 27, 2025
Drug: GenSci120; Placebo · For: Autoimmune Disease
Sites: Shanghai, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07040930 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Jul 5, 2026
Drug: GenSci120; Placebo · For: Rheumatoid Arthritis
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases.
Jiang W, Li L, Xue W, et al. · MAbs 2026
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.